340 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-ZC-FT-408333 May 03, 2019 - Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1? http://www.zacks.com/stock/news/406700/can-allergan-agn-beat-earnings-estimates-again-in-q1?cid=CS-ZC-FT-406700 May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release http://www.zacks.com/stock/news/405780/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release?cid=CS-ZC-FT-405780 Apr 30, 2019 - Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards? http://www.zacks.com/stock/news/405122/teva-teva-to-report-q1-earnings-whats-in-the-cards?cid=CS-ZC-FT-405122 Apr 29, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Is a Beat in Store for Editas (EDIT) This Earnings Season? http://www.zacks.com/stock/news/402783/is-a-beat-in-store-for-editas-edit-this-earnings-season?cid=CS-ZC-FT-402783 Apr 25, 2019 - On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Alkermes Reports Positive Data From Schizophrenia Study http://www.zacks.com/stock/news/377786/alkermes-reports-positive-data-from-schizophrenia-study?cid=CS-ZC-FT-377786 Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
These 3 Value Stocks Are Absurdly Cheap Right Now https://www.fool.com/investing/2019/04/09/these-3-value-stocks-are-absurdly-cheap-right-now.aspx?source=iedfolrf0000001 Apr 09, 2019 - Good bargains are hard to find in today's market. Here are a few overlooked stocks for you to capitalize on.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU http://www.zacks.com/stock/news/371503/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu?cid=CS-ZC-FT-371503 Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Allergan's AMD Drug Lowers Inflammation in Phase III Study http://www.zacks.com/stock/news/370088/allergans-amd-drug-lowers-inflammation-in-phase-iii-study?cid=CS-ZC-FT-370088 Apr 03, 2019 - Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

Pages: 1234567...34

<Page 2>